Approval · Notice of Compliance 11833 · 2010
ATOMOXETINE: Notice of Compliance 11833
Issued November 1, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11833
- Date
- November 1, 2010
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Selective norepinephrine reuptake inhibitor for attention-deficit / hyperactivity disorder (ADHD)
- Canadian reference product
- STRATTERA (Eli Lilly Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATOMOXETINE | 02358190 | — |
| ATOMOXETINE | 02358204 | — |
| ATOMOXETINE | 02358212 | — |
| ATOMOXETINE | 02358220 | — |
| ATOMOXETINE | 02358239 | — |
| ATOMOXETINE | 02358247 | — |
| ATOMOXETINE | 02358255 | — |
Medicinal ingredients
- ATOMOXETINE HYDROCHLORIDE 10 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 18 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 25 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 40 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 60 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 80 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 100 MG per CAP